{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.0","upperLimit":"90.8","value":"79.2"},{"groupId":"OG001","lowerLimit":"73.7","upperLimit":"95.8","value":"89.2"},{"groupId":"OG002","lowerLimit":"82.3","upperLimit":"99.6","value":"97.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"38"}],"units":"Participants"}],"description":"Overall survival in participants with multiple myeloma treated with Bortezomib (Velcade®) containing conditioning regimen and autologous as well as allogeneic transplantation.","dispersionType":"95% Confidence Interval","groups":[{"description":"Allogeneic Stem Cell Transplant: Fludarabine+Melphalan+Bortezomib followed by Allogeneic Rescue.\n\nBortezomib: AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m\\^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m\\^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).\n\nMelphalan: AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m\\^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m\\^2/day IV over 30 minutes.\n\nFludarabine: Days -6,-5,-4,-3 Fludarabine 30 mg/m\\^2/day IV\n\nAllogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with granulocyte colony-stimulating factor (GCSF) mobilization and infused fresh to recipients. Allogeneic donor stem cells may be cryopreserved if they cannot be infused","id":"OG000","title":"A: Allogeneic Stem Cell Transplant"},{"description":"Autologous Stem Cell Transplant: Melphalan+Bortezomib followed by Autologous Rescue.\n\nBortezomib: AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m\\^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m\\^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).\n\nMelphalan: AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m\\^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m\\^2/day IV over 30 minutes.\n\nAutologous Stem Cell Transplant: Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (G-CSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.","id":"OG001","title":"B: Autologous Stem Cell Transplant"},{"description":"Group B Expansion on Bortezomib Maintenance: Autologous Only.\n\nBortezomib: AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m\\^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m\\^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).\n\nMelphalan: AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m\\^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m\\^2/day IV over 30 minutes.\n\nAutologous Stem Cell Transplant: Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (G-CSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.","id":"OG002","title":"BE: Group B Expansion"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"End of 2 year, post transplant follow-up","title":"Overall Survival (OS) Rate","type":"SECONDARY","unitOfMeasure":"percentage"}